In vivo inhibition of the antibody response by a complement receptor- specific monoclonal antibody by unknown
BriefDefinitive Report
In Vivo Inhibition of the Antibody Response by
a Complement Receptor-Specific Monoclonal Antibody
By Birgitta Heyman,* Erik J. Wiersma,"$ and Taroh Kinoshita§
From the "Department of Medical and Physiological Chemistry, and the
tDppartment of Immunology, University of Uppsala, 23 Uppsala, Sweeden; and the
SDepartment of Bacteriology, Osaka University Medical School, Osaka 565, Japan
Summary
BALB/c mice were injected intravenously with three different monoclonal antibodies (mAbs)
specific for complement receptor 1 (CR1). Two of the mAbs crossreacted with CR2. 24 h later,
the mice were immunized with horse erythrocytes or keyhole limpet hemocyanin (KLH), and
the primary antibody response was measured. One of the anti-CR antibodies, 7G6, suppressed
>99% of the direct plaque-forming cell response against horse red blood cells (HRBC). The
same antibody markedly suppressed the serum antibody responses to both HRBC and KLH.
To be optimally suppressive, the mAb had to be injected before suboptimal concentrations of
antigen. The other two complement receptor-specific antibodies had very moderate, ifany, effects
on the antibody response. 7G6 was able to downregulate CRl and CR2 on the surface of B
cells and, in addition, to inhibit rosette formation with C3d-coated sheep erythrocytes (EC3d).
One of the antibodies with a weak effect downregulated only CRl. The other downregulated
both CRl and CR2, although not as efficiently as 7G6, and was unable to inhibit EC3d rosette
formation. We conclude that the reason 7G6 is outstanding in its suppressive capacity is that
it is the only mAb tested that functionally blocks CR2. The data suggest that CR2 is of crucial
importancein the initiationofa normal antibody response to physiological concentrations ofantigen.
T
he importanceof the complement system for the ability
ofanimals to mount a normal antibody response has been
demonstrated in a number of different ways (reviewed in refer-
ences 1 and 2). Treatmentof animals with cobra venom factor
(CVF), which leads to complement depletion by activating
the alternative pathway, suppresses the antibody response to
both thymus-dependent (3-5) and thymus-independent an-
tigens (6). Hereditary deficiencies in complement factors
Cl-C4, described in man, guinea pigs, and dogs, generally
lead to a low antibody response and poor induction of im-
munological memory (7-9). The enhancing effect of specific
Ig on the antibody response is abrogated when mice are treated
with CVF before immunization, or when mutant, non-
complement-activating IgM is used (10, 11). Moreover, sev-
eral in vitro studies have demonstrated that complement
receptor type 2 (CR2) is involved in B cell proliferation and
differentiation (12-15).
We have produced mAbs, specific for murine complement
receptors, that enabled us to design an in vivo experimental
system where CR1, or both CR1 and CR2, are functionally
blocked. This approach does not have the disadvantages of
in vitro systems and avoids the massive complement activa-
tion in CVF-treated mice. Our results demonstrate that
blocking of CR2 suppressed >99% of the primary in vivo




Female BALB/c mice, aged 8-16 wk, from Bomholdt-
gard, Ry, Denmark, were used throughout.
Antigens.
￿
HRBC (National Veterinary Institute, Hatunaholm,
Sweden) were stored in sterile Alsever's solution at 4°C. Before
use, erythrocytes were washed three times in PBS. Keyhole limpet
hemocyanine (KLH) (Calbiochem-Behring Corp., La Jolla, CA)
was dialyzed against PBS before use.
Antibodies. Three different rat mAbs, 8C12 (IgG2c), 7E9
(IgG2a), and 7G6 (IgG2b), with specificity for murine comple-
ment receptors were used (16, 17). The antibodies were purified
from ascites fluids ofnude mice by precipitationin ammonium sul-
fate at 40% saturation followed by ion exchange chromatography
on carboxymethyl-cellulose for 8C12 and DEAE-cellulose for 7E9
and 7G6. After dialysis against PBS, antibodieswere sterile filtered
and stored at -20°C.
Immunization.
￿
Anti-CR antibodies (200 ttg/mouse) and antigen
in 0.1 ml PBS were injected in the tail vein as described in the legends




direct haemolytic plaque assay was used (18).
ELISA. HRBC-specific IgG antibodies were assayed in an
ELISA, using alkaline phosphatase-conjugated protein A (Phar-
maciaFine Chemicals, Uppsala, Sweden) to detect bound antibody,
as described elsewhere (19). KLH-specific IgG was assayedin a similar
manner, but by using 50 Ag/ml of KLH as a coating agent and
detecting bound antibodies with alkaline phosphatase-conjugated
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CA). The data are expressed as absorbance values at 405 nm.
Results and Discussion
The anti-CR-antibodies 7G6, 7E9, and 8C12 are specific
fordifferent epitopes on CRl. 7G6 and7E9 crossreact exten-
sively with CR2, whereas 8C12 is monospecific forCR1(16,
17). 7G6 inhibits EC3d rosette formation and8C12 inhibits
EC3b rosette formation, whereas 7E9 is unable to inhibit
rosette formation. Upon intravenous injection of 200 lAg of
the antibodies in mice, 7G6 and 7E9 downregulate the ex-
pression of CR1 and CR2on murine B cells for7d, whereas
injection of 8C12 leads to downregulation of CR1 alone(17) .
To investigate the effect of CR on the antibody response,
groups of mice were injected intravenously with 200 t~g of
individual CR-specific mAb, followed after 24 h by an intra-
venous injection of HRBC. The results of representative ex-
periments are shown in Table 1. 7G6 is able to inhibit 99.6-
99.7% of the direct PFC response (Exp. 1-3) . The serum
IgG antibody levels are concomitantly suppressed. Thenearly
complete inhibition of the antibody response required that
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7G6 was administered before the antigen. When 7G6 was
injected 24 h after antigen, only 86% of the PFC response
was suppressed (Exp. 2, last group). Although this suppres-
sion is highly significant, the number of PFC is 42 times
higher than when 7G6 was injected 24 h before antigen in
the same experiment (8,370:200). Another requirement for
complete suppression was that suboptimal doses of HRBC
(3-4 x 105) were used. 7G6 injected before a high dose
(1.8 x 108) of HRBC caused only a slight reduction of the
PFC response andno reduction in serum IgGlevels (Exp. 5).
The otherCR-specific antibodies, 8C12 and 7E9, were com-
pared with 7G6 for ability to induce immunosuppression.
All antibodies were injected in the concentrations shown to
downregulate CR during at least 5 d (17). In an experiment
where 7G6 reduced the direct PFC response to 0.3% of the
control, 7E9 suppressed to 72% and 8C12 to 47% of the
control (Table 1, Exp. 3). Also, the suppression of the IgG
response was much more pronounced in the 7G6 groupthan
in the 8C12 and 7E9 groups (Exp. 3 and 4).
To examinetheeffect of anti-CR antibodies over a longer
time period, and to assess whether the suppressive effect on
' BALB/c mice (three to six per group) were immunized intravenously with the indicated amounts of HRBC. To some mice in each experi-
ment, 200 ug of anti-CR antibody was injected intravenously 24 h previously (except in Exp. 3, last group that received 7G6 24 h after
antigen).
t 5 d after antigen immunization, direct PFC/spleen were assayed and expressed as loglo/spleen (SD).
S Geometrical mean (antilog of the loglo value).
II Percent of control value (the group immunized with antigen alone).
1p value compared with the control group, as determined by student's t test .
" Absorbance at 405 nm (SD) of sera tested in ELISA.
# Numbers in parentheses are SD.
SS In this group, 7G6 was injected 24 h after HR-BC.
IIII p > 0.05.














1 3 x 105 HRBC 4.43 (0.42)# 26,873 100 0.34 (0.17)#
7G6 + 3 x 105 HRBC 2.03 (0.41) 107 0.4 .001 0.06 (0.03) 0.025
2 4 x 105 HR-BC 4.77 (0.09) 59,387 100 0.57 (0.08)
7G6 + 4 x 105 HRBC 2.30 (0.85) 200 0.3 .001 0 (0) 0.001
7G6ss + 4 x 105 HRBC 3.92 (0 .15) 8,370 14 .001 0.15 (0.13) 0.005
3 4 x 105 HRBC 4.23 (0.07) 16,888 100 0.73 (0.11)
7G6 + 4 x 105 HRBC 1.70 (0.30) 50 0.3 .001 0.03 (0.02) 0.001
8C12 + 4 x 105 HRBC 3.90 (0.39) 7,866 47 NSllll 0.32 (0.20) 0.005
7E9 + 4 x 105 HRBC 4.08 (0.10) 12,121 72 .05 0.49 (0.13) 0.025
4 4 x 105 HRBC ND 1.41 (0.05)
7G6 + 4 x 105 HRBC ND 0.37 (0.29) 0.001
8012 + 4 x 105 HRBC ND 0.94 (0.12) 0.001
7E9 + 4 x 105 HRBC ND 1.21 (0.18) NS
5 1.8 x 108 HRBC 4.91 (0.05) 81,549 100 0.82 (0.12)















Groups of four to five mice were immunized intrave-
nously with 4 x 105 HRBC (A) or 10 Ftg KLH (B) in PBS 24 h
after the intravenous administration of 200 jug 7G6 ("). Control
groups received antigen without prior 7G6 (O). Sera were tested in
ELISA. (""") p < 0.001; ("") p < 0.01; (") p < 0.05.
the antibody response affected also soluble protein antigens,
mice were bled 7, 14, and 21 d after immunization with 7G6
and HRBC or KLH (Fig. 1, A and B) . The IgG antibody
levels for both antigens were significantly suppressed during
the whole time period.
Thus, ofthe three anti-CR antibodies tested, 7G6 had the
strongest effect on the anti-HRBC response. This antibody
significantly suppressed the IgM and IgG responses to subop-
timal concentrations of two different thymus-dependent an-
tigens. We suggest that the reason 7G6 is outstanding in its
suppressive capacity is that it is the only mAb that function-
ally inhibits CR2, as demonstrated by its ability to down-
regulate the surface expression of CR1 and CR2, and, in ad-
dition, to inhibit EC3d rosetting. The rosette-inhibiting
capacity is probably important in blocking complement
receptors still remaining on the cell surface, and explains why
7E9 (which can only downregulate the surface expression,
but not inhibit rosetting) is not suppressive. The reason 8C12
is not suppressive is probably that it does not downregulate
CR2 but is monospecific for CR1.
It is unlikely that the almost complete suppression of the
antibody response by 7G6 is due to toxic effects on cells in-






was shown that the number of spleen cells with IgM, Ia,
and B220 on the surface was unchanged in 7G6-treated mice
(17). Second, the response to an optimal dose of antigen was
close to normal (Table 1, Exp. 5) and, third, LPS-induced
proliferation was not inhibited by the mAbs (not shown).
Negative effects mediated via crosslinking of the Fc and com-
plement receptor by 7G6 were not responsible for the im-
munosuppression, as these should also have been observed
with 7E9, and were not . The possibility that the CR-specific
antibodies crossreacted with Ig, and thereby influenced the
antibody response, was excluded by experiments that showed
that surface IgM expression was intact in treated mice (17).
Our data confirm earlier studies showing the importance
of C3 in antibody responses (1-15), and, in addition, dem-
onstrate, in an in vivo system, that signals via CR2 are of
crucial importance. Carter et al. (12) has shown that cross-
linking of surface Ig and CR2, but not CR1, led to increased
Cat` influx in human B cells in vitro. The data presented
here suggest thatcrosslinking of CR2 and Ig also have dra-
matic effects in vivo. This crosslinking could take place in
several ways, the simplest being that surface Ig on a B cell,
after binding to antigen, activates complement leading to
ligand binding to nearby CR2. Alternatively, immune com-
plexes containing preformed, complement-activating antibody
and antigen couldcrosslink CR2 and Ig on B cells. Binding
to surface Ig by an antigen that is able to activate comple-
ment via the alternative pathway would be a third way to
crosslink Ig and CR.
Another, not mutually exclusive, model for explaining the
complement dependence of the antibody response is that com-
plement mediates uptake of antigen by follicular dendritic
cells that also carry CR2. This model has received experimental
support by data showing that localization ofantigen and im-
mune complexes in the spleen is abolished after treatment
of mice with CVF (10, 20). However, since localization of
erythrocytes in the spleen is known to take place within hours
(21, 22), this mechanism cannot fully explain our findings.
When 7G6 was injected 24 h after HRBC, 86% of the PFC
response was still suppressed (Table 1, Exp. 3). Further ex-
perimentation is required to distinguish between direct effects
of complement on B cells and its effects on antigen localization.
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